FDA questions J&J's ACS data for Xarelto

FDA reviewers said the Phase III ATLAS ACS 2 TIMI trial evaluating anticoagulant Xarelto rivaroxaban from Johnson & Johnson (NYSE:JNJ) does not provide adequate evidence to support approval to reduce ...